Citation Impact
Citing Papers
Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine Expression
2021 StandoutNobel
Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment
2019
Current and emerging systemic therapies for cutaneous metastatic melanoma
2019
Advances in immunotherapy for melanoma
2016
Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro
2019
Targeted glycan degradation potentiates the anticancer immune response in vivo
2020 StandoutNobel
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth
2019
Engineering precision nanoparticles for drug delivery
2020 Standout
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer
2022 StandoutNobel
Psoriasis
2014
The application of nanotechnology in immune checkpoint blockade for cancer treatment
2018
Determining cell type abundance and expression from bulk tissues with digital cytometry
2019 Standout
Rheumatoid arthritis
2018 Standout
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
2016 Standout
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
2017
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
Ruxolitinib: A Review in Polycythaemia Vera
2015
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
2014
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Low-dose X-ray radiotherapy–radiodynamic therapy via nanoscale metal–organic frameworks enhances checkpoint blockade immunotherapy
2018
Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
2011
Next generation immune-checkpoints for cancer therapy
2018
Natural killer cells and other innate lymphoid cells in cancer
2018
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer
2017 StandoutNobel
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
2017
Emerging targets in cancer immunotherapy
2017
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Next generation of immune checkpoint therapy in cancer: new developments and challenges
2018
mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model
2022 StandoutNobel
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Targeting the indoleamine 2,3-dioxygenase pathway in cancer
2015
IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
2014
The promise of Janus kinase inhibitors in the treatment of hematological malignancies
2016
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment
2022 StandoutNobel
Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
2019
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
2019 Standout
Migrating into the Tumor: a Roadmap for T Cells
2017
Trial watch: IDO inhibitors in cancer therapy
2014
Down syndrome
2020 Standout
Renal cell carcinoma
2017 Standout
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Biological Therapies for Atopic Dermatitis: A Systematic Review
2021
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences
2018
Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
2015
A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)
2015
Immunotherapy for Colorectal Cancer
2017
Psoriasis Pathogenesis and Treatment
2019 Standout
Discovery of IDO1 Inhibitors: From Bench to Bedside
2017
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
2019
Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials
2021
Trisomy 21 consistently activates the interferon response
2016
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
2020
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer
2017
Ionizable lipid nanoparticles for in utero mRNA delivery
2021 StandoutNobel
Tolerance induction and microglial engraftment after fetal therapy without conditioning in mice with mucopolysaccharidosis type VII
2020
Studies of J ak/STAT 3 expression and signalling in psoriasis identifies STAT 3‐S er727 phosphorylation as a modulator of transcriptional activity
2013
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
2020
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
A phase I study of indoximod in patients with advanced malignancies
2016
Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study
2019
Regulatory T cells: a potential target in cancer immunotherapy
2018
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Baricitinib for the treatment of rheumatoid arthritis
2016
Works of Jack Shi being referenced
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers
2014
The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
2011
The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers
2011
Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation
2011
Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials
2018
A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)–only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer
2017
Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis
2012
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies
2017
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
2013
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
2015